Abbott's first quarter 2026 revenue of $11.16B beat estimates, driven by 13.2% growth in Medical Devices.

Abbott reported first quarter 2026 revenue of $11.16 billion, up 7.8% year-over-year, and adjusted EPS of $1.15, reflecting 6% growth. Comparable sales grew 3.7%, with results driven by strong performance in the Medical Devices and Established Pharmaceuticals segments which offset a decline in the Nutrition segment.

Key Highlights

• The Medical Devices segment delivered strong results, with reported sales growing 13.2% to $5.54 billion, led by double-digit growth in Electrophysiology (16.7%) and Rhythm Management (17.0%).
• Nutrition segment sales continued to decline, falling 7.7% on a comparable basis to $2.02 billion, reflecting lower sales volumes.
• Following the completed acquisition of Exact Sciences, the new Cancer Diagnostics segment contributed $96 million in sales, with comparable sales for the unit growing 13.4%.